{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infiltrating+Bladder+Urothelial+Carcinoma&page=2", "query": { "condition": "Infiltrating Bladder Urothelial Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infiltrating+Bladder+Urothelial+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:53:34.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06020807", "title": "Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Muscle Invasive Bladder Cancer", "Non-Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Bladder EpiCheck", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Nucleix Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 168, "start_date": "2019-09-05", "completion_date": "2020-01-08", "has_results": false, "last_update_posted_date": "2023-09-07", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06020807" }, { "nct_id": "NCT02767921", "title": "sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma", "Recurrent Bladder Carcinoma", "Stage I Prostate Cancer", "Stage I Renal Cell Cancer", "Stage II Bladder Urothelial Carcinoma", "Stage II Renal Cell Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radical Cystectomy", "type": "PROCEDURE" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-08-02", "completion_date": "2021-11-15", "has_results": false, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02767921" }, { "nct_id": "NCT03935347", "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-20", "completion_date": "2023-05-01", "has_results": false, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03935347" }, { "nct_id": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Implantable Micro-Device", "type": "DEVICE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin I", "type": "DRUG" }, { "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin II", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine/Carboplatin", "type": "DRUG" }, { "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin/Nivolumab", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Paclitaxel/Docetaxel/Ifosfamide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine/Carboplatin/Nivolumab", "type": "DRUG" }, { "name": "Enfortumab", "type": "DRUG" }, { "name": "Sacituzumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2024-06-14", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204614" }, { "nct_id": "NCT05987241", "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Muscle Invasive Renal Pelvis Urothelial Carcinoma", "Muscle Invasive Ureter Urothelial Carcinoma", "Muscle Invasive Urethral Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "cfDNA or ctDNA Measurement", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 992, "start_date": "2024-02-02", "completion_date": "2030-09-02", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 487, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987241" }, { "nct_id": "NCT06503614", "title": "A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer", "Non-Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Monalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Sfakianos", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-02-24", "completion_date": "2032-12-22", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 4, "location_summary": "Tampa, Florida • New Brunswick, New Jersey • New York, New York", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503614" }, { "nct_id": "NCT02812420", "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hydronephrosis", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant", "Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant", "Renal Pelvis Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage II Renal Pelvis Cancer AJCC v7", "Stage II Ureter Cancer AJCC v7", "Stage II Urethral Cancer AJCC v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Renal Pelvis Cancer AJCC v7", "Stage III Ureter Cancer AJCC v7", "Stage III Urethral Cancer AJCC v7", "Stage IV Renal Pelvis Cancer AJCC v7", "Stage IV Ureter Cancer AJCC v7", "Stage IV Urethral Cancer AJCC v7", "Ureter Urothelial Carcinoma", "Urethral Urothelial Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-03-07", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02812420" }, { "nct_id": "NCT04878029", "title": "Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-07-23", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04878029" }, { "nct_id": "NCT03419130", "title": "Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-07-18", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2018-12-07", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419130" }, { "nct_id": "NCT03744793", "title": "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant", "Metastatic Urothelial Carcinoma", "MTAP Negative" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-04-11", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-05-22T07:53:34.008Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03744793" } ] }